Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyMon, 03 Jun 2024 13:52:23 +0200Mon, 03 Jun 2024 15:45:00 +0200Imfinzi : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4771-en_3.pdfImfinzi : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4771-en_3.pdfMon, 03 Jun 2024 15:45:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 20, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/imfinziHuman medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 20, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/imfinziMon, 03 Jun 2024 11:52:00 +0200Human medicine